LAUSANNE,
Switzerland, Oct. 11, 2018 /PRNewswire/
-- Debiopharm International SA (Debiopharm), a
Swiss-based biopharmaceutical company and the Paul Scherrer
Institute (PSI), the largest research institute for natural and
engineering sciences in Switzerland, today announced a collaboration
to pursue the development of a radioconjugated minigastrin analogue
(Debio 1124) for cancer patients.
Debio 1124 is a new-generation peptide analogue of
minigastrin, coupled to the isotope 177Lutetium. It
belongs to the emerging class of Peptide Receptor Radionuclide
Therapies and has been designed to selectively radiate tumor cells
expressing the Cholecystokinin B Receptor (CCK2R). The compound can
also be used as a sensitive diagnostic tool so that an initial
imaging step allows the selection of patients who are most likely
to benefit from this innovative treatment.
Debio 1124 is currently being developed in advanced Medullary
Thyroid Cancer and will be further investigated in other tumor
types expressing CCK2R.
"Molecular-targeted radiotherapy has proven to be an
efficient way to direct the tumoricidal effects of radiation while
minimizing the potential damage of healthy tissues. We look forward
to exploring the potential of this innovative product in the clinic
and to providing new treatment options to well defined patient
groups".
Dr Carlos
Chanquia, Medical Director, Debiopharm
International
" PSI has once more
fulfilled its societal mission with the transfer of Debio 1124 into
direction of market maturity and which will hopefully contribute to
improve treatment outcome of cancer patients in the future. We are
proud that we will proceed with this mission in cooperation with a
Swiss based pharmaceutical company such as
Debiopharm".
Dr
Martin Béhé, Group Head, Center of
radiopharmaceutical sciences, PSI
About the Paul Scherrer
Institute
The PSI develops, builds and
operates large, complex research facilities and makes them
available to the national and international research community. The
institute's own key research priorities are in the fields of matter
and materials, energy and environment and human health. PSI is
committed to the training of future generations PSI is part of the
ETH Domain, with the other members being the two Swiss Federal
Institutes of Technology, ETH Zurich and EPFL Lausanne.
www.psi.ch
About
Debiopharm International SA
Part of
Debiopharm Group™, Debiopharm International SA focuses on the
development of prescription drugs that target unmet medical needs.
The company in-licenses and develops promising drug candidates. The
products are commercialized by pharmaceutical out-licensing
partners to reach out to the largest number of patients
worldwide.
www.debiopharm.com
Debiopharm International SA Contact
Christelle von
Büren
Communication
Coordinator
203110@email4pr.com
Tel: +41 (0)21 321 01
11
|
PSI Contact
Dagmar
Baroke
Head of
Communications
203110@email4pr.com
Tel:+41 (0) 56 310 29 16
|
View original
content:http://www.prnewswire.com/news-releases/debiopharm-international-sa-and-the-paul-scherrer-institute-announce-a-licensing-agreement-for-the-development-of-a-novel-targeted-radiotherapeutic-product-in-oncology-300729254.html
SOURCE Debiopharm International SA